Thank you for the question, Mr. Sorbara.
In terms of the patented medicines regulations, what we are really looking for is an opportunity to ensure that in health and innovation policies a whole-of-government approach is taken towards addressing the affordability challenges in terms of the pricing of pharmaceuticals in Canada, while at the same time ensuring that we work with the government to improve access and continue to support the innovation economy. Again, it's about taking a balanced approach in bringing health and innovation policies together.
Currently, the challenge, and the huge concern, is that the proposed changes on the affordability side are measures that are completely unprecedented and untested. Essentially, as an industry, we believe there are better solutions that can be implemented effectively and in a timely manner to help to address the affordability challenge that Health Canada and the Minister of Health are trying to solve without devastating the health research ecosystem and our ability to continue to attract investments into Canada.